Revolution Medicines Past Earnings Performance
Past criteria checks 0/6
Revolution Medicines's earnings have been declining at an average annual rate of -40.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 29.3% per year.
Key information
-40.7%
Earnings growth rate
37.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -29.3% |
| Return on equity | -36.2% |
| Net Margin | -76,423.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Revolution Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -567 | 88 | 115 |
| 30 Jun 24 | 1 | -519 | 79 | 76 |
| 31 Mar 24 | 5 | -484 | 72 | 0 |
| 31 Dec 23 | 12 | -436 | 62 | 0 |
| 30 Sep 23 | 26 | -331 | 54 | 253 |
| 30 Jun 23 | 30 | -296 | 49 | 154 |
| 31 Mar 23 | 35 | -259 | 45 | 0 |
| 31 Dec 22 | 35 | -249 | 41 | 0 |
| 30 Sep 22 | 30 | -245 | 38 | 0 |
| 30 Jun 22 | 27 | -224 | 36 | 0 |
| 31 Mar 22 | 27 | -208 | 33 | 0 |
| 31 Dec 21 | 29 | -187 | 30 | 0 |
| 30 Sep 21 | 29 | -169 | 28 | 0 |
| 30 Jun 21 | 40 | -143 | 25 | 0 |
| 31 Mar 21 | 42 | -126 | 23 | 0 |
| 31 Dec 20 | 43 | -110 | 21 | 0 |
| 30 Sep 20 | 46 | -95 | 20 | 0 |
| 30 Jun 20 | 46 | -85 | 18 | 0 |
| 31 Mar 20 | 48 | -71 | 15 | 0 |
| 31 Dec 19 | 50 | -62 | 12 | 0 |
| 30 Sep 19 | 48 | -57 | 12 | 0 |
| 31 Dec 18 | 20 | -49 | 9 | 0 |
Quality Earnings: 42Z is currently unprofitable.
Growing Profit Margin: 42Z is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 42Z is unprofitable, and losses have increased over the past 5 years at a rate of 40.7% per year.
Accelerating Growth: Unable to compare 42Z's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 42Z is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 42Z has a negative Return on Equity (-36.2%), as it is currently unprofitable.